About Jimena Vicencio
Articles by Jimena Vicencio, MD
A Fixed-Duration Regimen for CLL: Acalabrutinib + Venetoclax Results from the AMPLIFY TrialDec 17, 2024
HealthTree Research Results: Patients Share their Experiences with Talquetamab TherapyDec 12, 2024
The Best of ASH 2024Dec 09, 2024
HealthTree Research Results: How Side Effects Influence Myeloma Patient DecisionsDec 08, 2024
HealthTree Research Results: Patient Preferences When Weighing Myeloma Treatment FactorsDec 08, 2024
First Day of ASH 2024- Busy Times in Leukemia Research!Dec 06, 2024
FDA Reviews Belantamab Mafodotin for Approval in Relapsed/Refractory Multiple MyelomaDec 05, 2024
Real-world Results for Preventing Infections in CLL and Non-Hodgkin Lymphoma PatientsNov 15, 2024
New Treatment Coming for High-Risk Smoldering Myeloma?Nov 12, 2024
Azer-cel, a New CAR T-Cell Therapy for DLBCLNov 08, 2024
Low-Risk MDS Patients See Limited Benefit from Traditional Anemia Treatment (ESAs)Oct 30, 2024
Recruiting Trials for New Therapy Regimen for AML PatientsOct 29, 2024
What Influences the Outcomes of Follicular Lymphoma Patients?Oct 16, 2024
What Factors Impact the Outcomes in Myelofibrosis Patients?Oct 15, 2024
New CAR T for Relapsed/Refractory Myeloma Shows Promising Phase 1 ResultsOct 14, 2024
CAR-T Therapy Trial for Relapsed/Refractory Acute Myeloid LeukemiaOct 09, 2024
New Clinical Trial with Armored CAR T-cellsOct 01, 2024
What Is VEXAS Syndrome?Sep 27, 2024
What is Light-Chain Only Myeloma?Sep 26, 2024
New All-Oral Triplet for Older Myeloma Patients on the HorizonSep 24, 2024
New Trial Required for Iomab-B FDA ApprovalSep 17, 2024
Enhancing CAR T-Cell Therapy in Multiple MyelomaSep 16, 2024
What is Tumor Lysis Syndrome?Sep 13, 2024
Managing the Unique Side Effects of Talquetamamb with Dr. Ajai Chari, MDSep 08, 2024
